   Program Organisers Abstracts Participants |
2004
Uppsala, Sweden
| C. Ambery (1), L. Aarons (1) Population Pharmacokinetics and Response of ICL670 a Novel Oral Iron Chelator in Beta-Thalassaemia Patients |
| JS Barrett (1,4), A Zuppa (1,3), M Schreiner (5) and PC Adamson (1, 2, 4) Esmolol Population Pharmacokinetics in Critically-ill, Pediatric Patients |
| JS Barrett, J Skolnik, MR Gastonguay and PC Adamson The Value of Priors and Prior Uncertainty in Clinical Trial Simulation: Case Study with Actinomycin-D in Children with Cancer |
| E.Y.L. Blair(1), D.R. Mould(2), S.J. Clarke(3), L.P. Rivory(4), A.J. McLachlan(1) Pharmacokinetic-Pharmacodynamic Modelling of Raltitrexed in Patients with Advanced Solid Tumours |
| K. Brendel (1), E. Comets (1), C. Laveille (2), R. Jochemsen (2), F. Mentré (1) Comparison of several prediction errors on concentrations for model evaluation |
| K.C. Carlsson (1), N.O. Hoem (2), T. Glauser (3), A. A. Vinks (4). Can clinically useful population PK models for carbamazepine in pediatric epilepsy patients be developed based on routine therapeutic drug monitoring (TDM) data? |
| A. Lanner (1), X. Xiaonian (1), T. Donovan (2), B. Charles (1) Population Modelling of the Absolute Bioavailability and Pharmacokinetics of Phenobarbitone in Infants with Seizures |
| Jean-Eric Charoin(1), Philippe Jacqmin(2), Ludger Banken(3), Sian Lennon(4) and Karin Jorga(1) Population Pharmacokinetic Analysis of Trastuzumab (Herceptin) following Long-Term Administration Using Different Regimens. |
| Xuejun Chen, Al Corey, Suresh Mallikaarjun, Steve Bramer Population Pharmacodynamic Analysis of QTc Prolongation vs. Plasma Concentration |
| Emmanuelle Comets, France Mentré and François Gimenez Cerebral uptake of mefloquine enantiomers with and without theP-gp inhibitor elacridar (GF1210918) in mice |
| C. Dansirikul(1), L.E. Friberg(1), S.B. Duffull(1), R.G. Morris(2), S.E. Tett(1) Bayesian Population Pharmacokinetic Analysis of Sirolimus |
| C. Dartois (1), C. Laveille (2), B. Tranchand (1,3), M. Tod (4), P . Girard (1,5) What is the Value of Uncertainty Parameter Estimates provided by Different Population PK Methods? |
| Filip De Ridder (1), An Vermeulen (2) and Vladimir Piotrovskij (2) Modelling and simulation of the incidence of adverse events in clinical trials. |
| Michael G Dodds(1), Paolo Vicini(1), Jennifer E Visich(2) and Mark Rogge(2) A Population PK Model for Recombinant Factor XIII in Congenitally Deficient Subjects |
| Michael G Dodds(1), Andrew C. Hooker(1) and Paolo Vicini(1) Robust Population Pharmacokinetic Experiment Design |
| Aris Dokoumetzidis and Leon Aarons Propagation of population pharmacokinetic information using a Bayesian approach |
| Duffull SB(1), Waterhouse TH(2), Redman S(1), Eccleston JA(2) A real time optimal design for model discrimination and parameter estimation for itraconazole population pharmacokinetics |
| F. Fiorentini (2), M. Simeoni (1), I. Poggesi (2), G. Westerberg (2), M. Rocchetti (2) An example of application of the population approach to toxicological studies. |
| L.E. Friberg, C. Dansirikul and S.B. Duffull Simultaneous fit of competing models as a model discrimination tool in Bayesian analysis |
| C Segura1, E Bandrés2, I F Trocóniz1, J García-Foncillas2,O Sayar1, C Dios-Vieitez1, M J Renedo1, M J Garrido1 Modelling of the effect of Topotecan on B cell subsets in tumor bearing rats. |
| H. Jones(1), R. Gieschke(2) Incorporating uncertainty and variability into PBPK based predictions of human PK |
| S. Gisbert, L. Aarons and M. Rowland. Different approaches to the development of a WBPBPK model with a series of barbiturates using population modelling |
| Andy Grieve Adaptive Designs : Bayesian & Non-Bayesian Approaches |
| Isabelle Pouliquen, Lutz Harnisch A Population PK/PD Model for Cortisol Suppression |
| N.O. Hoem (1), P. Beringer (2) A non-parametric (NPAG) population PK model of orally and intravenously administered linezolid. |
| N.Holford (1), P.Chan (1), J.Nutt (2) Disease Progression in Parkinson’s Disease – Evidence for Protective Effects of Drug Treatment |
| Andrew Hooker, Michael G. Dodds, Paolo Vicini Evaluating the predictive power of the Fisher information matrix in population optimal experimental design |
| F. Hourcade-Potelleret, C. Weber, B. Fotteler and N. Frey Population PK Analysis in Sparse Data and Flexible Sampling Time Conditions |
| Dymphy Huntjens (1), Anne Chain (1), David Spalding (2), Meindert Danhof (1) and Oscar Della Pasqua(1,3) Population semi-parametric modelling of the pharmacokinetics of rofecoxib in rats |
| Daniel M. Jonker (1), Derek Leishman (2), Rob Wallis (2), Peter E. Milligan (2) and E. Niclas Jonsson Development and validation of a mechanism-based PK/PD model for the in vitro-in vivo prediction of QT prolongation by dofetilide |
| E. Niclas Jonsson Graphical display of population data |
| H.M. Jones(1), K. Jorga(2), T. Lavé(1) PK extrapolation from animal to man: the good, the bad and the ugly. An overview of the performance of different methods applied across the project portfolio at Roche |
| H. Silber (1), P. Stetina (1), B. McHugh (2), R. Gieschke (2), N. Frey (2), P. Vicini (3), U.S.H. Simonsson (1), M.O. Karlsson (1) A disease model for the regulation of the glucose-insulin system |
| CMJ Kirkpatrick(1), SB Duffull(1), ML Barclay(2), N Patton(3), GA Moore(4), MP Doogue( 1) Population pharmacokinetic analysis of high-dose oral busulphan for bone marrow transplant in adults and children |
| Maria C. Kjellsson, Mats O. Karlsson Fitting Proportional Odds model to Ordered Categorical Data using the NLMIXED Procedure |
| I. Knutsson (1), L. Aarons (2), S.Callies (3) Bayesian analysis of a patient dataset using prior information from normal volunteers and from another patient group |
| Holger Kraiczi (1), Marianne Frisén (2) Effect of Uncertainty About Population Parameters on Pharmacodynamics-Based Prediction of Clinical Trial Power - A Method for Sensitivity Analysis |
| Niels Rode Kristensen A Deconvolution Method for Linear and Nonlinear Systems based on Stochastic Differential Equations |
| Niels Rode Kristensen Using Stochastic Differential Equations for PK/PD Model Development |
| E Lamont (1), AH Thomson (2,3), M Dawber (2), L Semple (4), E Bell (4), RA Seaton (4) Population Pharmacokinetics of Teicoplanin in Outpatient Home Parenteral Antibiotic Therapy (OHPAT) |
| Marc Lavielle(1) and the Monolix research group(2) SAEM in MATLAB: an alternative to linearization |
| R. H. Leary (1), R. Jelliffe (2), A. Schumitzky (2), R.E. Port (3) Accurate Maximum Likelihood Estimation for Parametric Population Analysis |
| T. Lehr (1), C. Tillmann (2), A. Staab (2), D. Trommeshauser (2), H.G. Schaefer (2), C. Kloft (1) Clock time as a control variable for gall bladder emptying in an enterohepatic circulation model |
| A. Lemenuel-Diot (1,2), C. Laveille( 2), N.Frey (2), R. Jochemsen (2), A. Mallet (1) Mixture Modelling for the Detection of Subpopulations in a Pharmacokinetic/Pharmacodynamic analysis |
| C. Lia Liefaard (1), Bart A. Ploeger (1,2), Carla F.M. Molthoff (3), Ronald Boellaard (3), Adriaan A. Lammertsma (3), Meindert Danhof (1,2), Rob A. Voskuyl (1,4) Application of Population Pharmacokinetic Analysis for Quantification of in vivo Binding Properties in the Rat Brain by Positron Emission Tomography |
| K.H. Liesenfeld, EU. Gräfe-Mody, A. Staab, H.G. Schaefer Population pharmacokinetics of a new anticoagulant drug in clinical development |
| Lars Lindbom, Pontus Pihlgren and E. Niclas Jonsson PsN Toolkit, a collection of computer intensive methods for population PK/PD |
| John C Lukas(1), Martina Samiotaki(2), Maria Kontou(2), Rosario Calvo(3), Panos Macheras(1), Tasos Zografidis(3), Georgios Kyriakides(4) The cytochrome P450 3AP1 variant genotype shows correlation with the true clearance in a renal transplant population |
| Hugo Maas, Meindert Danhof, Oscar Della Pasqua Comparison of sumatriptan and naratriptan using a markov model approach |
| Al Maloney Using SAS for non-linear mixed modelling – An overview |
| B. Mc Hugh, N. Frey Population PK and PK/PD Analyses of an Enzyme Inhibitor in Healthy Volunteers |
| K. Ogungbenro, G. Graham and L. Aarons The Design of Population Pharmacokinetic Studies: Sample Size Determination |
| R. V. Overgaard(1,2), E. N. Jonsson(3), C. W. Tornøe(4), H. Madsen(2) Non-Linear Mixed Effects Models with Stochastic Differential Equations - Implementation of an Estimation Algorithm |
| Perez-Ruixo, JJ; Kimko, HC; Chow, A; Piotrovskij, V NONMEM Implementation of Cell Lifespan Models for Hematological Drug Effects |
| M. Pfister, S. Krishnaswami, S. Rohatagi Characterization of Cortisol Circadian Rhythm and Lack of Cortisol Suppression by a New Corticosteroid, Ciclesonide |
| V. Piotrovsky(1), G. Kopia(2), G.W. Vetrovec(3), D. Rizik(4), David Snead(2) Population pharmacokinetic analysis of concentration data after implantation of sirolimus-eluting Bx Velocity stent in patients |
| B. Ploeger(2), N. Houwing(1), A. Bom(3), M.P. van Iersel(1), D. Zollinger(1), M. Danhof(2) The reversal of rocuronium-induced neuromuscular block by the cyclodextrin ORG25969: model development and validation |
| Poggesi I (1), Simeoni M (2), Germani M(1), De Nicolao G(2), Rocchetti M(1) Population modeling of tumor growth in untreated xenografted mice |
| Willem de Winter (1), Teun Post (1), Joost DeJongh (1,2), Richard Urquhardt(3), Ian Moules (3), David Eckland (3) and Meindert Danhof (1,2) A Mechanistic Disease Progression Model for Type 2 Diabetes Mellitus and Pioglitazone Treatment Effects |
| Sylvie Retout, Emmanuelle Comets and France Mentré Comparison between the Fedorov-Wynn algorithm and the Simplex algorithm for population designs optimisation using a model of the HIV viral load decrease |
| Jakob Ribbing and E. Niclas Jonsson Learning about Covariate Relations in the Patient Population Based on Data from Multiple Studies – Consequences of Different Approaches |
| Annick Rousseau, Aurélie Prémaud, Pierre Marquet Modeling the complex pharmacokinetic profiles of cyclosporin and of mycophenolate observed in the early post-transplantation period. |
| Adeline Samson (1), Marc Lavielle (2) and France Mentré (1) Stochastic Approximation EM algorithm in nonlinear mixed effects models: an evaluation by simulation |
| Radojka Savic(1), Daniël M. Jonker(1), Thomas Kerbusch(2), Mats O. Karlsson(1) Evaluation of a transit compartment model versus a lag time model for describing drug absorption delay |
| O. Sayar(1), L. Bueno(1), M.J. Garrido(1), F. Rombout(2), I.F. Trocóniz(1) Comparison of different models to describe simultaneously the kinetics of parent drug and metabolites after oral administration. |
| Simeoni M (1), Poggesi I (2), Germani M(2), De Nicolao G(1), Rocchetti M(2). Population modeling of tumor growth inhibition in vivo: application to anticancer drug development |
| Michael K. Smith(1), Mark F. Morris(1), Ieuan Jones(1), Andy P. Grieve(1), Keith Tan(2) An adaptive design for dose-response using the Normal Dynamic Linear Model. |
| Michael K. Smith(1), Scott Marshall(2), John Huggins(2). A Bayesian design and analysis for dose-response using informative prior information |
| C. W. Tornøe (1,2,3), H. Agersø (1), R. V. Overgaard (2), H. A. Nielsen (2), H. Madsen (2), E. N. Jonsson (3) Stochastic differential equations in NONMEM |
| I.F. Trocóniz (1), M.J. Garrido (1), and F. Rombout (2) Pharmacokinetic/Pharmacodynamic Modelling of the Analgesic Effects of Tramadol in the Paediatric Population |
| M Valle, M Yritia, R Antonijoan, G Urbano, MR Ballester, MJ Barbanoj Population pharmacokinetic/pharmacodynamic modeling of the possible tolerance development after a single oral dose of different BZD-GABAa agonists. |
| Vermeulen, An; Piotrovsky, Vladimir and De Ridder, Filip Modeling the occurrence of orthostasis using a longitudinal logistic regression model |
| Sandra A.G. Visser (1), Björn Sällström (1), Tomas Forsberg (2), Svante B. Ross (3), Lambertus A. Peletier (4) and Johan Gabrielsson (1) Modeling of drug- and system-related changes in body temperature: application to drug-induced hypothermia, long-lasting tolerance development and diurnal variation in body temperature |
| E. Tousset (1), C. Reners (1) & B. Vrijens (1-2) Identifying and minimizing major sources of variability in population pharmacokinetic studies |
| Willi Weber, Diether Rueppel, Heiner Speth Comparing efficacy of 10mg vs 20mg ARAVA in treatment of rheumatoid arthritis: A Population PK / PD Analysis |
| Justin J Wilkins (1), Grant Langdon (1), Helen McIlleron (1), Goonaseelan Pillai (2), Peter J Smith (1) and Ulrika SH Simonsson (3) A population pharmacokinetic-enzyme model for rifampicin autoinduction and bimodal absorption in pulmonary tuberculosis patients |
| James Wright Adaptive dose-finding in two-dimensions: A phase 1 oncology example |
| A.S. Zandvliet(1,2), A.D.R. Huitema(1,2), M.E. de Jonge(1,2), R. den Hoed(3), R.W. Sparidans(3), V.M. Hendriks(4,7), W. van den Brink(5,7), J.M. van Ree(6,7), J.H. Beijnen(1,2,3) Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine |
| Matthew L. Zierhut(1), Mark C. Peterson(2), Marc R. Gastonguay(3), Steven W. Martin(2), Paolo Vicini(1), Pirow J. Bekker(2), Donna Holloway(2), Philip T. Leese(4) Development and Evaluation of a Population PK/PD Model for Fc-OPG in Healthy Postmenopausal Women |
| Pieter Janssen(1,2), Nicolaas H. Prins(2), Pieter J. Peeters(2), Klaas P. Zuideveld(3) and Romain A. Lefebvre(1) Quantification of 5-HT7 receptor efficacy distribution throughout the canine stomach using the operational model of agonism. |
